Ciprofol EC50 for Inducing Loss of Consciousness in Elderly Patients

Elderly Patients Clinical Trial

Official title:

Ciprofol EC50 for Inducing Loss of Consciousness in Elderly Patients: an Exploratory Study Based on Dixon's Up-and-Down Method

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06253078
• Other study ID #: IRB-2024-76(IIT)
• Status: Recruiting
• Phase: Phase 4
• Start date: April 2, 2024
• Est. completion date: December 30, 2025

Study information

• Verified date: May 2024
• Source: Zhejiang Cancer Hospital
• Contact: Xiaochun Jin
• Phone: +8657188122564
• Email: ec[@]zjcc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ciprofol is a recently introduced novel sedative drug. In comparison to the traditional propofol, ciprofol exhibits a higher affinity for GABA A receptors, approximately 4-5 times that of propofol, and possesses fewer side effects, particularly notable in respiratory depression and injection pain. In the context of general anesthesia induction, recent research has confirmed a 100% success rate in the induction of general anesthesia for elderly patients (65-80 years old) undergoing non-cardiac surgery with a dosage range of 0.2mg/kg-0.4mg/kg ciprofol. However, for elderly patients aged 65 and above, even up to 85 years old, it is currently not entirely clear what dosage should be selected for patients in different age groups. Consequently, we have designed this trial with the aim of exploring the dosage requirements of ciprofol during general anesthesia induction among elderly patients in various age brackets.

Methods: This is a prospective, non-controlled, non-randomized, single-blind study. Elderly patients aged 65 years and older were enrolled in the study with American Society of Anesthesiologists (ASA) physical status I or II undergoing general anesthesia. All patients were divided into five groups according to age, and the corresponding initial dose of ciprofol administered was selected according to the grouping, with subsequent doses of ciprofol determined according to the Dixon up-and-down method. At least seven crossover points were obtained before the conclusion of the study.The primary outcomes were the dose of ciprofol administered at the time of loss of consciousness (mg/Kg) and the plasma concentration of ciprofol.

Description:

After received the approvement of ethics committee of the Cancer Hospital of the University of Chinese Academy of Sciences (approval number IRB-2024-76(IIT)). The study was registered before patient enrollment in Clinicaltrials.Written informed consent was obtained from all participants. The study was performed from Jan 1, 2024 to Dec 31, 2025. 150 patients aged 65 years and above, ASA physical status I or II, undergoing surgery under general anesthesia and who were not allergic to the study drug were included in this study. Basic monitoring such as 3-lead electrocardiogram, pulse oximetry, and noninvasive blood pressure were arranged preoperatively. All patients were divided into five groups according to age, The initial dose of ciprofol for the first elderly patient was 0.2-0.4 mg/kg, the initial concentration was 0.4 mg/Kg for patients aged 65-74 years, 0.3 mg/Kg for patients aged 75-84 years, and 0.2 mg/Kg for patients aged 85 years or older, and the ciprofol doses for adjacent patients were set to be equidistantly spaced up and down by 0.05 mg/kg. Evaluation of the eyelash reflex and speech reflex was performed after intravenous infusion of ciprofol to observe whether LOC occurred within 4 min. After loss of consciousness, sufentanil (5ug/ml, diluted in 0.9% saline) and rocuronium bromide were given for endotracheal intubation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 30, 2025
• Est. primary completion date: December 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years to 105 Years

Eligibility

Inclusion Criteria:

• 65 = age years;

• ASA physical state I and II;

• Hadn't a history of allergy to the drugs used in this study;

Exclusion Criteria:

• America Society of Anesthesiologists (ASA) class >III;

• Allergic to anesthetic solutions or the drugs used in this study;

• Body mass index (BMI) = 20 or = 30 kg/m2;

• Using hypnotics, opioid analgesics, or anti-anxiety medications;

• Known or suspected heart failure (ejection fraction <40%), severe respiratory disease, renal or metabolic disease

• Refuse to participate or participate with other clinical investigators ;

Related Conditions & MeSH terms

• Elderly Patients
• Unconsciousness

Intervention

Drug:
• Ciprofol dose 0.4mg/Kg
The initial dose of ciprofol was 0.4mg/Kg for induction in this group.
• Ciprofol dose 0.3mg/Kg
The initial dose of ciprofol was 0.3mg/Kg for induction in this group.
• Ciprofol dose 0.2mg/Kg
The initial dose of ciprofol was 0.2mg/Kg for induction in this group.

Locations

Country	Name	City	State
China	Jiangling Wang	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ciprofol EC50 (mg/Kg) for loss of consciousness	Use up-and-down method to evaluate the Ciprofol EC50 for loss of consciousness in different age groups.	From loss of consciousness (LOC) to 10 minutes after trachea intubation.
Secondary	Plasma concentration of ciprofol when LOC.	Measure the plasma concentration of ciprofol when LOC.	From the start of induction to loss of consciousness, approximately 4 to 8 minutes after start of induction.
Secondary	The mean artery pressure	Hemodynamic fluctuation during induction	From entering the OR to 10 minutes after trachea intubation.
Secondary	The heart rate	Hemodynamic fluctuation during induction	From entering the OR to 10 minutes after trachea intubation.
Secondary	Incidence of adverse events	Measuring and recording the adverse events such as hypotension, hypertension, bradycardia and tachycardia during induction period.	From entering the OR to 10 minutes after trachea intubation.